CellentraTech Files Patent Application Covering W2993, Advancing Intellectual Property Strategy for Lead KRAS G12D Program
Patent filing strengthens protection around W2993 and supports CellentraTech’s targeted mRNA-LNP oncology platform
[Cambridge, Massachusetts— Feb,2025] — CellentraTech, a preclinical in vivo gene-therapy biotechnology company developing targeted mRNA-LNP medicines and in vivo immune-cell engineering programs, today announced the filing of a patent application covering W2993, the company’s lead intracellular KRAS G12D payload.
W2993 is being developed as an mRNA-encoded intracellular payload designed to inhibit KRAS G12D following delivery into targeted cells. The molecule serves as the lead payload in CellentraTech’s two targeted mRNA-LNP co-lead programs, A20T013/W2993 and G059/W2993, which are being developed for distinct tumor settings and routes of administration.
CellentraTech has reported that W2993 has demonstrated in vitro inhibition and specificity in company-generated studies. The company has also completed cellular uptake and endocytosis work supporting progression toward integrated address-dependent delivery and in vivo confirmation.
The patent filing is intended to strengthen CellentraTech’s intellectual-property position around W2993 and related therapeutic applications while supporting the company’s broader strategy of combining differentiated cell or tissue targeting with intracellular disease-modifying payloads.
Thomas, Chief Technology Officer of CellentraTech, commented:
“The filing around W2993 represents an important step in converting our scientific work into a durable intellectual-property asset. W2993 was designed to address KRAS G12D from inside the cell, and our in vitro work has given us a foundation to move from payload validation toward the more demanding question of integrated, targeted delivery. We believe protecting the payload, its use within our product architecture, and the associated development strategy is important as we advance both lead programs and evaluate broader opportunities across the platform.”
CellentraTech’s development model separates the major components of an in vivo therapeutic product—cell or tissue address, delivery system and intracellular payload—so that each can be evaluated independently before being integrated into a final product configuration. W2993 provides a shared payload strategy across the company’s two lead targeted mRNA-LNP programs while allowing each program to maintain its own route-, address- and indication-specific development requirements.
The company’s next development priorities for the W2993-based programs include confirmation of address-dependent cellular delivery, integrated product performance and route-relevant in vivo validation. All CellentraTech programs remain investigational, and no clinical safety or efficacy has been established.
About CellentraTech
CellentraTech is a preclinical in vivo gene-therapy biotechnology company focused on precision oncology and the development of medicines that combine targeted cellular access with intracellular therapeutic intervention. The company’s pipeline is anchored by two targeted mRNA-LNP co-lead programs incorporating the W2993 KRAS G12D payload and is supported by a broader portfolio that includes in vivo engineered-TCR programs, CAR-mRNA concepts, additional KRAS payload opportunities and in vivo gene-editing research.
CellentraTech’s platform is designed around an address-plus-payload strategy: selecting an accessible cell or tissue target, pairing it with a disease-relevant intracellular payload, and integrating both with a route and delivery architecture appropriate for the intended biological compartment. The company is advancing its programs through disciplined preclinical validation, intellectual-property development and IND-enabling planning.
Media / Corporate Contact
CellentraTech
[Name]
[Email]
[Website]
This press release contains forward-looking statements regarding CellentraTech’s research programs, intellectual-property strategy and future development activities. Actual results may differ materially. All programs described are investigational; no clinical safety or efficacy has been established.
